Corbus Pharmaceuticals Holdings, In... (CRBP)

$0.1447

+0.00 (+3.36%)
Rating:
Recommendation:
Buy
Symbol CRBP
Price $0.1447
Beta 2.034
Volume Avg. 4.07M
Market Cap 18.128M
Shares () -
52 Week Range 0.1-0.624
1y Target Est -
DCF Unlevered CRBP DCF ->
DCF Levered CRBP LDCF ->
ROE -75.30% Strong Sell
ROA -56.52% Strong Sell
Operating Margin -
Debt / Equity 76.01% Buy
P/E -
P/B 0.43 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CRBP news


Mr. Yuval Cohen
Healthcare
Biotechnology
NASDAQ Global Market

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.